Receptor, Anaphylatoxin C5a
"Receptor, Anaphylatoxin C5a" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A G-protein-coupled receptor that signals an increase in intracellular calcium in response to the potent ANAPHYLATOXIN peptide COMPLEMENT C5A.
| Descriptor ID |
D044087
|
| MeSH Number(s) |
D12.776.543.750.695.024 D12.776.543.750.705.833.550
|
| Concept/Terms |
Receptor, Anaphylatoxin C5a- Receptor, Anaphylatoxin C5a
- CD88 Antigen
- Antigen, CD88
- Receptor, Complement 5a
- CD88 Antigens
- Anaphylatoxin C5a Receptor
- Antigens, CD88
- C5a Receptors
- Receptors, C5a
- Complement 5a Receptor
|
Below are MeSH descriptors whose meaning is more general than "Receptor, Anaphylatoxin C5a".
Below are MeSH descriptors whose meaning is more specific than "Receptor, Anaphylatoxin C5a".
This graph shows the total number of publications written about "Receptor, Anaphylatoxin C5a" by people in this website by year, and whether "Receptor, Anaphylatoxin C5a" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2002 | 0 | 1 | 1 |
| 2006 | 1 | 0 | 1 |
| 2016 | 0 | 2 | 2 |
| 2017 | 0 | 5 | 5 |
| 2018 | 1 | 1 | 2 |
| 2019 | 1 | 0 | 1 |
| 2020 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Receptor, Anaphylatoxin C5a" by people in Profiles.
-
Complement cascade in severe forms of COVID-19: Recent advances in therapy. Eur J Immunol. 2021 07; 51(7):1652-1659.
-
Treatment of Rare Inflammatory Kidney Diseases: Drugs Targeting the Terminal Complement Pathway. Front Immunol. 2020; 11:599417.
-
Complement and tissue factor-enriched neutrophil extracellular traps are key drivers in COVID-19 immunothrombosis. J Clin Invest. 2020 11 02; 130(11):6151-6157.
-
The Complement C5a-C5aR1 GPCR Axis in COVID-19 Therapeutics. Trends Immunol. 2020 11; 41(11):965-967.
-
Association of COVID-19 inflammation with activation of the C5a-C5aR1 axis. Nature. 2020 12; 588(7836):146-150.
-
Complement 5a Receptor Polymorphisms Are Associated With Panton-Valentine Leukocidin-positive Staphylococcus aureus Colonization in African Pygmies. Clin Infect Dis. 2019 02 15; 68(5):854-856.
-
Complement Receptor C5aR1 Inhibition Reduces Pyroptosis in hDPP4-Transgenic Mice Infected with MERS-CoV. Viruses. 2019 01 09; 11(1).
-
IL-6 Receptor Inhibition by Tocilizumab Attenuated Expression of C5a Receptor 1 and 2 in Non-ST-Elevation Myocardial Infarction. Front Immunol. 2018; 9:2035.
-
Blockade of the C5a-C5aR axis alleviates lung damage in hDPP4-transgenic mice infected with MERS-CoV. Emerg Microbes Infect. 2018 Apr 24; 7(1):77.
-
Participation of delta annexin A3 in the ribosomal protein S19 C-terminus-dependent inhibitory mechanism of the neutrophil C5a receptor through delta lactoferrin. Pathol Int. 2018 Feb; 68(2):109-116.